NEW YORK, Feb. 21, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on DEPO, DRRX, ENDP, and IONS which can be accessed for free by signing up to www.wallstequities.com/registration. Today's pre-market research on WallStEquities.com is centered on the Pharmaceutical Manufacturing industry,
Shares in Newark, California headquartered Depomed Inc. saw a slight decline of 0.67%, ending Tuesday's trading session at $7.39. The stock recorded a trading volume of 2.51 million shares, which was higher than its three months average volume of 1.35 million shares. The Company's shares have gained 19.00% over the last three months. The stock is trading 6.40% below its 50-day moving average. Moreover, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have a Relative Strength Index (RSI) of 49.77.
On February 07th, 2018, Depomed announced that members of its senior management will participate in a fireside chat at the RBC Capital Markets 2018 Global Healthcare Conference on February 22nd, 2018, at 11:30 a.m. EST in New York. The fireside chat will be webcast live and may be accessed under the Investor Relations' page of the Company's website. Get the full research report on DEPO for free by clicking below at: www.wallstequities.com/registration/?symbol=DEPO
Cupertino, California headquartered DURECT Corp.'s stock declined 2.68%, closing the day at $1.09 with a total trading volume of 316,539 shares. The Company's shares have advanced 14.09% in the previous three months and 7.92% over the past year. The stock is trading 1.11% above its 50-day moving average. Additionally, shares of DURECT, which researches and develops medicines based on its epigenetic regulator and drug delivery programs, have an RSI of 46.42.
On February 14th, 2018, DURECT announced that its licensee, Pain Therapeutics (PTIE), reported on February 13th, 2018 that it has resubmitted the New Drug Application for REMOXY® ER to the U.S. Food and Drug Administration (FDA). REMOXY ER is designed as an abuse-deterrent, extended release, capsule formulation of oxycodone, a prescription drug for severe pain. PTIE stated that it expects a six-month review cycle by FDA, and that it expects to be notified by FDA of a Prescription Drug User Fee Act date within 60 days. Access the free research report on DRRX now by signing up at: www.wallstequities.com/registration/?symbol=DRRX
On Tuesday, shares in Dublin, Ireland headquartered Endo International PLC recorded a trading volume of 3.10 million shares. The stock ended the day 1.60% lower at $6.77. The Company's shares are trading below their 50-day moving average by 9.54%. Furthermore, shares of Endo, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have an RSI of 45.02.
On February 06th, 2018, Endo announced the initiation of two identical Phase-3 RELEASE clinical trials of collagenase clostridium histolyticum (CCH) for the treatment of cellulite. The multicenter, randomized, double-blind, placebo-controlled RELEASE studies will evaluate the safety and efficacy of CCH in reducing the appearance of cellulite.
On February 14th, 2018, research firm B. Riley FBR, Inc. initiated a 'Buy' rating on the Company's stock, with a target price of $10 per share. Are you already registered with Wall St. Equities? Do so now for free, and get the report on ENDP at: www.wallstequities.com/registration/?symbol=ENDP
Carlsbad, California headquartered Ionis Pharmaceuticals Inc.'s stock dropped slightly by 0.12%, finishing yesterday's session at $49.99 with a total trading volume of 586,878 shares. The Company's shares have advanced 6.50% over the past year. The stock is trading below its 50-day moving average by 2.41%. Additionally, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 49.32.
On February 13th, 2018, Ionis Pharma announced that it will host a live webcast on February 27th, 2018, at 11:30 a.m. ET to discuss its 2017 financial results and report on pipeline and business progress. The webcast may be accessed on the Company's website. Aspiring Member, please take a moment to register below for your free research report on IONS at: www.wallstequities.com/registration/?symbol=IONS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-drug-makers-stocks----depomed-durect-endo-and-ionis-pharma-300601747.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!